Rerun: Lars Fruergaard Jørgensen CEO of Novo Nordisk

This podcast episode explores the complexity of obesity as a disease and the challenges it poses globally. It discusses the role of genetics and lifestyle factors in weight gain and the impact of changing demographics and increased accessibility to unhealthy food. The episode also highlights the development of new medicines, like GLP-1, that offer hope for effective weight management. It delves into the balance between generating profits and making a global impact in healthcare research. Furthermore, it addresses the challenges faced by the pharmaceutical industry in balancing profits and helping people, as well as the differences between the pharmaceutical industries in the US and Europe. The episode concludes by discussing the importance of addressing obesity as a medical intervention with high societal returns, the influence of cultural differences on decision-making processes, and the advantages of longevity and sustainable growth in a pharmaceutical company.